Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
134.4 EUR | +0.16% | -3.09% | -5.25% |
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- The company's earnings growth outlook lacks momentum and is a weakness.
- With an enterprise value anticipated at 3.89 times the sales for the current fiscal year, the company turns out to be overvalued.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-5.25% | 35TCr | - | ||
+39.82% | 73TCr | C+ | ||
+33.10% | 59TCr | B | ||
+14.23% | 32TCr | B- | ||
+0.86% | 28TCr | C+ | ||
+14.36% | 24TCr | B+ | ||
+9.26% | 21TCr | B- | ||
-6.13% | 20TCr | A+ | ||
+4.51% | 16TCr | C+ | ||
-2.05% | 16TCr | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- JNJ Stock
- JNJ Stock
- Ratings Johnson & Johnson